Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

PI: Dr.ssa Claudia Proto 

The study consists of four phases:  

1. a pre-screening phase to select patients characterized by a MSC high risk level; 
2. ia screening period for completion of all screening assessments and subsequent randomization;  
3. a treatment period;  
4. a post-treatment follow-up period. 

All participants who meet the eligibility criteria will be 1:1 randomized to receive: 

- single agent immune checkpoint inhibitor (Pembrolizumab) in the control arm  

- immune checkpoint inhibitor and chemotherapy (Pembrolizumab and chemoterapy) in the experimental arm